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pharmacophore-guided discovery 
of CDC25 inhibitors causing cell 
cycle arrest and tumor regression
Zeynep Kabakci1, Simon Käppeli  1, Claudio Cantù2,3,4, Lasse D. Jensen5, Christiane König1, 
Janine Toggweiler4, Christian Gentili1, Giovanni Ribaudo6, Giuseppe Zagotto6, Konrad Basler4, 
Lorenzo A. Pinna7, Giorgio Cozza  8 & Stefano Ferrari  1
CDC25 phosphatases play a key role in cell cycle transitions and are important targets for cancer 
therapy. Here, we set out to discover novel CDC25 inhibitors. Using a combination of computational 
methods, we defined a minimal common pharmacophore in established CDC25 inhibitors and 
performed virtual screening of a proprietary library. Based on the availability of crystal structures for 
CDC25A and CDC25B, we implemented a molecular docking strategy and carried out hit expansion/
optimization. Enzymatic assays revealed that naphthoquinone scaffolds were the most promising 
CDC25 inhibitors among selected hits. At the molecular level, the compounds acted through a mixed-
type mechanism of inhibition of phosphatase activity, involving reversible oxidation of cysteine 
residues. In 2D cell cultures, the compounds caused arrest of the cell cycle at the G1/S or at the G2/M 
transition. Mitotic markers analysis and time-lapse microscopy confirmed that CDK1 activity was 
impaired and that mitotic arrest was followed by death. Finally, the compounds induced differentiation, 
accompanied by decreased stemness properties, in intestinal crypt stem cell-derived Apc/K-Ras-mutant 
mouse organoids, and led to tumor regression and reduction of metastatic potential in zebrafish 
embryo xenografts used as in vivo model.
The Cell Division Cycle 25 family encompasses three highly conserved members of dual specificity phosphatases 
that specifically target Cyclin-Dependent Kinases (CDKs), acting as dose-dependent inducers of cell cycle tran-
sitions1,2. CDC25A primarily activates CDK2/CycE and CDK2/CycA at the G1/S transition and in S-phase3, 
though it also cooperates with CDC25B at the onset of mitosis4. CDC25B initiates CDK1/CycB activation at 
centrosomes during the G2/M transition4,5 and CDC25C causes full activation of CDK1 at mitotic entry6.
Genetic studies showed that thermosensitive cdc25 yeast mutants could be reversibly arrested in the cell cycle7, 
providing the first demonstration of a regulatory role for CDC25. The mouse Cdc25A gene was shown to be the 
only family member endowed with an essential function during embryonic development8.
Overexpression of CDC25, particularly CDC25A and CDC25B, has been observed in a variety of human 
cancers and correlates with poor clinical prognosis9. Interestingly, although CDC25A overexpression alone is 
insufficient to drive tumor initiation, CDC25A has a clear role as rate-limiting oncogene in transformation by 
RAS10. Furthermore, point mutations in CDC25C have a critical role in the pathology of acute myelogenous 
leukemia (AML)11.
Since the identification of vitamin K as potent CDC25 inhibitor, compounds based on the structure of vitamin 
K, as well as on other structures, have been developed as CDC25 inhibitors12–19. However, most compounds failed 
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to keep up with expectations, either due to rapid metabolism in tumor-bearing SCID mice20 or for not completing 
clinical trials21, and have thus not attained approval.
In light of the recent discovery that CDC25 is the therapeutic target of choice in triple-negative breast can-
cers, namely those that are negative for estrogen-, progesterone- and HER2-receptor expression and that are 
unresponsive to standard therapy22, we set out to develop novel CDC25 inhibitors. To this end, we conducted 
a pharmacophore-guided drug discovery program that led to the identification of scaffolds of the naphthoqui-
none group displaying inhibition of CDC25 in enzymatic assays. In cultured cells, the most potent compounds 
induced inhibition of CDK1 activity and function, with block of mitotic transition followed by cell death. In 
mouse Apc/K-Ras mutant duodenal organoids, low doses of CDC25 inhibitors caused arrest of proliferation and 
expression of differentiation markers, whereas high doses induced cell death. In zebrafish embryos, used as in vivo 
xenograft model, the CDC25 inhibitors led to tumor regression and reduction of metastases.
Results
Pharmacophore-guided library screening and hit selection. To the end of retrieving novel CDC25 
inhibitors from an in silico virtual library that was built from a proprietary database of synthetic molecules, we 
implemented a number of computational strategies (Fig. S1A), according to established protocols23. First, CDC25 
inhibitors belonging to three classes - natural products, quinones and electrophiles24 - were subjected to a linear 
fragmentation process25 implemented in MOE Suite26, in which input structures were split into small pieces by 
removing the least “scaffold-like” extremity until indivisible essential fragments were obtained. Next, the molec-
ular entities returned by this process, ordered by increasing size, were used to build a series of pharmacophore 
models (Fig. S1B). The latter were optimized until the achievement of a final model, representative of the chemical 
features of scaffolds obtained from the fragmentation process. Finally, this model was used to examine a propri-
etary library through a pharmacophore-guided virtual screening process (MOE Suite). Compounds obtained 
from the first round of hit selection and belonging to different molecular families were tested at fixed concentra-
tion on recombinant CDC25A (Table S1). Reference compound in all tests was the established CDC25 inhibitor 
NSC-663284, a para-quinonoid derivative of vitamin K27. Naphthoquinones UPD-140 (Fig. 1A, 2-(2′,4′-dihy-
droxyphenyl)-8-hydroxy-1,4-naphthoquinone) and UPD-176 (Fig. 1B, 5-hydroxy-2-(2,4-dihydroxyphenyl)
naphthalene-1,4-dione) appeared to be the most effective inhibitors of CDC25 phosphatase activity. Based on 
the structure of UPD-140 and UPD-176, and exploiting the crystal structure of CDC25B28, along with available 
homology models for CDC25A and CDC25C, we performed hit expansion/optimization through a molecular 
Figure 1. Structure and docking of CDC25 inhibitors. (A,B) Structure of 2-(2′,4′-dihydroxyphenyl)-8-
hydroxy-1,4-naphthoquinone (UPD-140) and 5-hydroxy-2-(2,4-dihydroxyphenyl)naphthalene-1,4-dione 
(UPD-176). (C) Molecular docking of UPD-140 into CDC25B catalytic site.
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docking strategy (Fig. 1C). Identification of pockets and surface sites through the localization of regions of tight 
atomic packing suggested two close cavities suitable to accommodate the compounds. Both cavities are highly 
conserved in the three enzymes and one is superimposable with the phosphatase catalytic site (Table 1). Starting 
point for prioritization of scaffolds was the presence of a quinone moiety, which appeared to be a necessary con-
dition for optimal anchoring of compounds in CDC25 catalytic pocket. Reassessment of the library, based on the 
structure of UPD-140 and UPD-176, followed by in vitro enzymatic assays revealed eight additional compounds 
as effective inhibitors of CDC25 phosphatase activity, all of them being 1,4-naphthoquinones with hydroxyl 
groups either in position 5 or 8 (Table S2).
Enzymatic characterization and profiling of CDC25 inhibitors. Selected naphthoquinone-based 
inhibitors were examined in dose-response assays on CDC25 phosphatases. Compounds UPD-786, UPD-793, 
UPD-795 and UPD-140 appeared to be the most potent inhibitors, displaying IC50 of 0.89 μM, 0.92 μM, 1.25 μM 
and 1.42 μM on CDC25A that are comparable to the IC50 of NSC-663284 (0.38 μM) (Figs 2A and S2A)29. A similar 
pattern of inhibition was observed on CDC25B and CDC25C, though with slightly higher IC50 values (Fig. 2A). 
Kinetic analysis conducted with UPD-795 revealed a mixed mechanism of enzyme inhibition, as indicated upon 
data analysis with the mixed-model inhibition equation30 (Table S3 and Fig. S2B), confirming the predictions of 
docking studies.
Considering that quinones are oxidizing agents, known for their ability to generate reactive oxygen species 
(ROS) in biological systems, and that the Cys residue in CDC25 active site is highly susceptible to oxidation31, we 
decided to assess a possible role for redox reactions in the inhibition of CDC25 by the most potent naphthoqui-
nones described here. To this end, we treated CDC25A with an excess of the reducing agent DTT before addition 
of the compounds at a concentration proximal to their IC50. The data indicated that the presence of DTT in the 
reaction prevented inhibition of CDC25 (Fig. 2B).
Furthermore, since the quinone scaffolds so far described in the literature are in part reversible and in part 
irreversible CDC25 inhibitors, we decided to assess the mode of action of our most potent naphthoquinone 
inhibitors. To this end, we pre-incubated CDC25A with excess compound (5 μM, corresponding to ~3x IC50) and 
subsequently assayed for remaining phosphatase activity upon 10-fold dilution of the pre-incubation mix (hence 
at 0.5 μM compound). The data showed that the enzyme activity remaining upon dilution of the pre-incubation 
mix was comparable to the activity detected upon direct treatment of the phosphatase with 0.5 μM compounds, 
indicating a reversible mode of action (Fig. 2C). This was not the case for NSC-663284, which is an established 
irreversible inhibitor of CDC25 (Fig. 2C).
To assess specificity, we profiled two of the most potent CDC25 inhibitors, UPD-795 and UPD-140, against 
a panel of protein phosphatases. The data revealed that, when tested at concentrations close to the IC50 for 
CDC25A, both compounds also inhibited human PP5 activity to about 50% (Table S4), whereas none of the other 
phosphatases examined was affected.
Cellular characterization of CDC25 inhibitors. To assess CDC25 inhibitors in cells we performed via-
bility assays on HeLa cells upon treatment with increasing compound doses. The data revealed IC50 of 1.08 μM, 
1.41 μM, 0.90 μM and 1.20 μM for UPD-176, UPD-790, UPD-787 and UPD-140 respectively (Fig. 3A), all val-
ues being lower than that of the reference compound NSC-663284 (IC50 = 2.57 μM) (Fig. S3A). Compounds 
UPD-738 and UPD-786 appeared to be slightly less potent than NSC-663284, though both displayed IC50 values 
<10 μM (4.40 μM and 6.50 μM, respectively) (Fig. S3B).
To evaluate in a cellular context the oxidation-based mechanism of inhibition, we treated cells with the 
aminothiol N-Acetylcysteine, an antioxidant, prior to administration of the compounds. At compound doses 
exceeding 3x the IC50 (5 μM), cell viability was rescued to ~50% of controls in the presence of the reducing agent 
(Fig. 3B), hence confirming results obtained in biochemical assays.
Cavity 1 Cavity 2
CDC25A CDC25B CDC25C CDC25A CDC25B CDC25C
Tyr 387 Tyr 428 Tyr 332 Asp 336 Glu 377 His 281
Cys 431 Cys 473 Cys 377 Ile 338 Ile 379 Ile 283
Phe 433 Phe 475 Phe 379 Gly 339 Gly 380 Gly 284
Ser 434 Ser 476 Ser 380 Tyr 345 Phe 386 Cys 290
Glu 436 Glu 478 Glu 382 Asp 356 Asp 397 Asp 301
Gly 438 Gly 480 Gly 384 Leu 357 Leu 398 Leu 302
Arg 440 Arg 482 Arg 386 Lys 358 Lys 399 Lys 303
Met 489 Met 531 Met 435 Cys 442 Cys 484 Cys 388
Arg 446 Arg 488 Arg 392
Arg 450 Arg 492 Arg 396
Glu 462 Glu 504 Glu 408
Leu 463 Met 505 Leu 409
Table 1. Residues lining the two cavities of CDC25 retrieved by the Site Finder approach. The catalytic cysteine 
in cavity 1 of each phosphatase is shown in italics.
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To assess effects of the CDC25 inhibitors on cell cycle progression we administered compounds to HeLa cells 
and examined DNA content by flow cytometric analysis. In asynchronous HeLa cells, treatment with UPD-596, 
UPD-738, UPD-786, UPD-793 or UPD-795 caused an increase of the G1 population, indicating that G1/S was 
likely the point of action for these compounds. On the other hand, UPD-176, UPD-787 and UPD-790 were most 
effective in causing accumulation of cells at G2/M (Fig. 3C). Similar results were obtained in U2OS cells (Fig. S4). 
Since HeLa cells can be conveniently synchronized at specific points in the cell cycle (Fig. S5A), they were treated 
with UPD-176 or UPD-795 at the time of release from a double-thymidine block (early S-phase). Under these 
conditions, progression through S-phase was effectively held in check as compared to controls (Fig. S5B). To 
precisely assess effects of the compounds on the G1/S transition, HeLa cells were synchronized at G2/M, released 
to allow completion of mitosis and re-entry into the cell cycle, and treated in mid-G1 with UPD-176, UPD-
596, UPD-738 or UPD-793. Analysis of cell cycle progression at 12 h post-release, a time when control cells 
entered S-phase, showed that UPD-176, UPD-738 and UPD-793 effectively blocked cells in G1, whereas UPD-
596 appeared to be ineffective in this respect (Fig. 3D). To assess the effect of compounds on the G2/M transition, 
double-thymidine synchronized HeLa cells were released and treated with UPD-176, UPD-787, UPD-790 or 
UPD-140 5 h upon release, namely in late S-phase (Fig. S5A). Flow cytometric analysis of cell cycle progression 
at 12 h post-release, when control cells largely moved to the next G1 phase, showed that all compounds caused 
accretion of the G2/M peak, with UPD-790 apparently being the most effective of all (Fig. 3E). To exclude the 
possibility that the observed cell cycle arrest would be secondary to genotoxic effects, we examined the biomarker 
γ-H2AX at the onset of mitosis in cells treated with the compounds. The data showed that, in comparison to a 
potent genotoxic agent, no damage to DNA occurred upon treatment with the naphthoquinone compounds 
(Fig. S6).
To visualize the execution of mitosis, we administered compounds to HeLa cells 5 h upon release from a 
double-thymidine block, and monitored cells by time-lapse microscopy for the subsequent 14 h. We observed 
that whereas control cells timely progressed through mitosis and moved to the next cycle, cells treated with UPD-
787 could not complete mitotic transition and died before reaching G1 (Fig. 4A). A similar pattern was obtained 
Figure 2. Enzymatic analysis of CDC25 inhibitors. (A) Dose-response studies with the indicated compounds 
on recombinant CDC25A, CDC25B and CDC25C. (B) CDC25A was treated in the presence or the absence of 
the reducing agent DTT (10 mM) prior to incubation with the compounds at a concentration proximal to their 
IC50 (1.25 μM). (C) Left: CDC25A was treated with the indicated compounds at a concentration ~3x IC50 (5 μM 
for UPDs and 2 µM for NSC663284), diluted 10-fold and assayed for phosphatase activity at the remaining 
compound concentration (0.5 and 0.2 μM, respectively). Right: As comparison, CDC25A was assayed upon 
direct addition of compounds at 0.5 or 0.2 μM concentration, respectively.
www.nature.com/scientificreports/
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with compounds UPD-790 and UPD-176 (Fig. S7A and data not shown). To better appreciate the response to 
inhibitors at the onset of mitosis, we administered low doses (5 μM) of UPD-787 or UPD-790 to synchronized 
HeLa Kyoto cells, which carry mCherry-H2B and GFP-α-tubulin. We observed a failed attempt to round up and 
execute mitosis, which was followed by membrane blebbing and death (Fig. S7A and Movies M1–M3). Western 
blot analysis revealed caspase-mediated cleavage of PARP-1, a signature of apoptosis, in cells treated with the 
compounds (Fig. S7B).
Biochemical analysis of mitotic markers at 10 h from the double-thymidine block-release showed decreased 
MPM2 epitopes in treated cells, a read out for CDK1 activity, and reduced Histone H3 phosphorylation at Ser10, a 
read-out for chromosome condensation (Fig. 4B). To directly assess cellular CDK1 activity under these conditions 
we used antibodies recognizing phosphorylated Thr14 or Tyr15, two sites in the P-loop of CDK1 catalytic domain, 
the phosphorylation of which hampers kinase activity and that are selectively dephosphorylated by CDC2532,33. 
As expected, at 12 h from the double-thymidine block-release point, control cells progressed to the G1 phase of 
the next cycle displaying low pThr14/pTyr15-CDK1, whereas cells treated with the compounds accumulated at 
G2/M (Fig. 4F) displaying high pThr14/pTyr15-CDK1 (Fig. 4C–E). The level of pTyr15-CDK1 in cells treated with 
CDC25 inhibitors appeared to be intermediate between that of cells treated with Ro-3306, a specific inhibitor of 
CDK1, and of cells treated with Nocodazole, an agent that interferes with tubulin polymerization causing arrest 
at pro-metaphase with active CDK1 (Fig. 4E).
CDC25A overexpressing cell lines are sensitive to CDC25 inhibitors. To determine whether cancer 
cells overexpressing CDC25 are sensitive to treatment with the compounds identified in this study, we initially 
selected cell lines that carry activating bi-allelic mutation of K-Ras (G12S) and are reported to express high level 
of CDC25B (http://www.proteinatlas.org/). However, Western blot analysis of cytoplasmic and nuclear extracts 
of such cell lines (A549 and Colo741) compared to HeLa, revealed lack of correspondence between the mRNA 
levels reported in databases and actual protein expression (Fig. S8). Similar results were obtained upon analysis of 
CDC25A and CDC25C protein expression (Fig. S8). Given the lack of an appropriate cell line model, we resorted 
to a system where CDC25A is expressed in a tetracycline-dependent manner and has been previously described34. 
Viability assays showed that cells grown in the absence of tetracycline, a condition inducing ectopic expression of 
HA-CDC25A to high extent, remained sensitive to treatment with UPD-176 or UPD-787 (Fig. 5A,B). P-values, 
determined by non-linear regression analysis of the data and curve fitting comparison, resulted to be < 0.0001 
for both UPD-176 and UPD-787 (Fig. S9), indicating that the difference between tet-induced and non-induced 
cells was significant.
CDC25 inhibitors arrest growth of Apc/K-Ras intestinal organoids. Having established the 
effect of CDC25 inhibitors on the growth of cells in monolayer cultures, we addressed the ability of selected 
compounds to affect the growth of organoid cultures. Since CDC25A cooperates with, and is rate-limiting in 
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Figure 3. CDC25 inhibitors affect cell viability and the cell cycle. (A) HeLa cells were treated with increasing 
amounts of compounds and cell viability was determined. (B) Cells were treated in the presence or the absence 
of NAC before administration of compounds at doses ~3x IC50 (5 μM) and cell viability was determined. (C) 
Cells were treated with the indicated compounds (10 μM, 15 h). NSC663284 was used as comparison (5 µM, 
15 h). DNA was stained with DAPI. (D) HeLa cells were synchronized at G2/M by treatment with Thymidine 
(1 mM, 15 h), release in full medium followed by addition of the CDK1 inhibitor Ro-3306 (9 μM, 15 h). Five 
hours upon release from Ro-3306, the indicated compounds were added (10 μM) and cells were harvested and 
analyzed 12 h upon release from Ro-3306. (E) HeLa cells were synchronized at G1/S by 2x thymidine block-
release, compounds (10 μM) were added at 5 h and cells were analyzed at 12 h from release.
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tumorigenesis induced by Ras10, we generated and cultured 3D-organoids from stem cells of the intestinal crypts 
of Apc/K-Ras mice35. The latter carry the loss-of-function mutation Apc1638N combined with the villinCre-driven 
gain-of-function K-RasG12V mutation36. Upon seeding Apc/K-Ras organoids along with UPD-176 (5 μM), we 
observed that growing spheroids partially invaginated (Fig. 6A), indicating reduction of stem cell renewal accom-
panied by increased differentiation37, whereas higher doses of the compound caused massive death (data not 
shown). Consistent with the pattern of invagination at low compound treatment, immunofluorescence confo-
cal imaging revealed augmented expression of lysozyme, a marker for cells exiting the proliferative compart-
ment of the crypt and acquiring a differentiated state (Fig. 6B). Quantitative RT-PCR performed on the stemness 
marker Lgr5 and on the differentiation markers Lysozyme and Cryptdin confirmed the confocal microscopy data 
(Fig. 6C).
CDC25 inhibitors cause tumor regression and block the formation of metastasis in an in vivo 
model. Next, we evaluated the effects of UPD-176, UPD-140 and UPD-738 on growth and metastatic poten-
tial of HCT116 tumors in vivo using a zebrafish xenograft model38. The compounds were well tolerated by the 
developing zebrafish embryos at the effective dose (10 µM) and did not cause signs of overt toxicity. Treatment 
of tumor-bearing fish larvae with UPD-140 for three days (from day 2 to day 5) caused a dramatic regression 
of the tumors, which were reduced to approximately half the size of the initial volume (p < 0.00784, Fig. 7A,B). 
The concurrent reduction in metastasis achieved borderline significance (p < 0.0604, Fig. 7A,C). Treatment with 
UPD-176 or UPD-738 displayed a tendency towards tumor regression, although not significant in comparison 
to vehicle (DMSO)-treated embryos (p < 0.1830 and p < 0.0609, respectively). For these compounds, also the 
Figure 4. CDC25 inhibitors impair the execution of mitosis. (A) Phase contrast stills of HeLa cells 
synchronized by 2x thymidine block-release, treated with vehicle alone or UPD-787 (10 μM) 5 h upon release 
and visualized from 7.5 h to 21.5 h upon release (4 frames/h). (B) Western blot analysis of MPM2 epitopes 
and Histone H3 phosphorylation (pSer10) in HeLa cells treated as in (A) and examined at 10 h upon release 
from the 2x thymidine block. (C) Western blot analysis of CDK1 (pThr14 and Tyr15, respectively) from HeLa 
cells treated as in (A) and examined at 10 h upon release from the 2x thymidine block. (D) Flow cytometric 
analysis of CDK1-pTyr15 in cells treated as in (A) and examined 12 h upon release from the 2x thymidine block. 
Nocodazole (0.4 μg/ml) and Ro-3306 (9 μM) were used as controls for the level of CDK1 phosphorylation. 
Staining with secondary antibody only (left panel) was used to subtract self-fluorescence. (E) Quantification of 
positive events gated as shown in (D). (F) DNA content (DAPI staining) of the cells shown in D.
www.nature.com/scientificreports/
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variation of metastatic burden upon treatment with either compound did not appear to be significant (Fig. 7A–C). 
Taken together, these data demonstrate that inhibiting CDC25 may be an effective strategy to induce tumor 
regression and inhibit metastasis, in vivo.
Discussion
Precision oncology is centered on the principle of continuous molecular interrogation of tumors and on the use 
of dedicated pharmacological tools to maximize success in therapy. Constant monitoring is essentially intended 
to assess resistance39 and reveal pathways to which tumors may become addicted during treatment40.
CDC25 phosphatases are overexpressed in a variety of human cancers9,41, are rate-limiting in tumorigenesis 
induced by Ras10, and were recently proposed as target of choice in unresponsive, triple-negative breast cancer22. 
In this study, we set out to identify novel CDC25 inhibitors. Taking advantage of knowledge gained in previous 
drug discovery programs13,42, we initially defined a pharmacophore that is common to compounds belonging 
to three distinct classes of established CDC25 inhibitors (Fig. S1). Performing a ligand-based virtual screen of a 
proprietary library, we identified naphthoquinone inhibitors of CDC25 phosphatases and conducted molecular 
docking studies on the crystal structure of CDC25B (Fig. 1, Tables S1 and S2). The phenyl moiety present in our 
scaffold represents a novel feature with respect to the chemical structure of previously described naphthoquinone 
Figure 5. Cells overexpressing CDC25 are sensitive to CDC25 inhibitors. (A) U2OS Tet-OFF cells expressing 
HA-CDC25A were treated with the indicated compounds and cell viability was determined. P-values were 
determined by non-linear regression analysis and curve fitting comparison using the extra sum-of-squares 
F-test. (B) Western blot (WB) analysis of HA-CDC25A expression in the presence or absence of tetracycline. 
PR: Ponceau Red staining.
www.nature.com/scientificreports/
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inhibitors of the CDC25 family14. The interactions established by the R groups of the phenyl ring with residues 
located in the two cavities of CDC25 (Table 1) likely allow efficient anchoring of the naphthoquinone scaffold 
(Fig. 1), contributing to ameliorate potency in enzymatic and cellular assays. Biochemical studies on the identi-
fied compounds revealed a mixed mechanism of inhibition for all CDC25 members (Fig. S2), possibly indicating 
binding of the compounds to catalytic (Fig. 1C) and allosteric sites of the phosphatase, as also reported for other 
CDC25 inhibitors18,19,27,43,44. Mechanistically, we observed that compounds acted reversibly on CDC25 (Fig. 2C), 
likely through oxidation of the catalytic cysteine (Fig. 2B), a mode of action that we confirmed in cells (Fig. 3B). 
Such mechanism is compatible with a model proposed for CDC25 inhibitors31, according to which the thiolate 
group of the active-site cysteine undergoes very rapid conversion to sulfenic acid and it is protected from further 
conversion into irreversibly inactivated sulfinic acid by a back-door cysteine located in close proximity to the 
catalytic residue.
Cellular experiments showed that the most potent compounds arrested cells at the G1/S or the G2/M tran-
sition (Fig. 3D,E). Considering that these compounds displayed similar kinetics of inhibition on the three puri-
fied CDC25 isoforms (Fig. 2A), the reason for such preferential point of action in the cell cycle remains to be 
investigated. Interestingly, administration of compounds at the time of release from double-thymidine treatment 
showed minimal progression to S-phase at 6 hours of release (Fig. S5B). This may indicate that either turnover 
of the compound occurred during this time or, more likely, that the amount of CyclinE/CDK2 complex built 
up while cells accumulated at the point of forced arrest (i.e., early S-phase) was sufficient to support cell cycle 
progression despite inhibition of CDC25. The latter hypothesis is corroborated by the observation that when 
compounds were added in mid-G1, transition to S-phase was effectively blocked (Fig. 3D).
Figure 6. CDC25 inhibitors block the growth of K-Ras-dependent intestinal organoids. (A) Organoids 
reproducing duodenal crypts and derived from Apc/K-Ras mouse small intestine (left) were grown in 
the presence of UPD-176 (right). Phase contrast stills were obtained at 48 h of treatment. (B) Confocal 
immunofluorescence microscopy of Apc/K-Ras organoids treated as in A and stained for proliferation 
(β-catenin) or differentiation (lysozyme) markers. DNA was stained with DAPI. (C) qRT-PCR on cDNA 
obtained from control- and UPD-176-treated organoids was conducted using primers to the indicated markers.
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Since quinones undergo reduction to form semiquinone radicals or hydroquinones that, in turn, can react 
with oxygen to form superoxide radicals and/or hydrogen peroxide45, hence affecting a number of metabolic 
processes in the cell, we examined DNA damage induction as a possible side-effect relevant to the overall cellular 
response observed. Specifically, we quantified the biomarker γ-H2AX in synchronized cells that were treated 
with compounds. The data excluded the possibility that the cell cycle arrest observed in response to compound 
treatment could be secondary to genotoxic effects (Fig. S6).
To examine the cellular mechanism of action for the compounds described in this study, we focused on activa-
tion of CDK1 and entry into mitosis. Analysis of the extent of Thr14/Tyr15 phosphorylation, as indicator of kinase 
activation, and phosphorylation of CDK1 substrates, as indicator of kinase activity, revealed that the inhibitors 
effectively impaired both responses (Fig. 4B–E). Chromosome condensation normally occurring in prophase was 
also impaired in compound-treated cells, in line with flow cytometry data attesting a G2/M arrest under these 
conditions (Fig. 4B,F). Visual inspection of cells treated with the compounds showed that they could not execute 
mitosis, in line with our biochemical evidence, but rather underwent massive death (Fig. 4A). Administration 
of low concentration of the inhibitors to HeLa cells carrying mCherry-H2B allowed appreciating failed attempts 
to round up for mitosis, followed by membrane blebbing and death according to an apoptotic pattern (Fig. S7, 
Movies M2 and M3).
Enzymatic profiling of two of the most potent CDC25 inhibitors on a panel of phosphatases revealed PP5 as 
the only other target of the compounds (Table S4). PP5 controls a number of cellular processes including pro-
liferation, migration and DNA damage. Interestingly however, PP5 activity is normally off due to folding of an 
N-terminal inhibitory domain onto the catalytic site, with ligand-mediated release of auto-inhibition occurring 
in response to cellular cues46. Hence, we argue that the specific G1/S and G2/M responses that we describe in this 
study are genuine effects of the identified compounds on CDC25 phosphatases.
Considering that CDC25A and CDC25B are overexpressed in a variety of human cancers9 and CDC25A was 
demonstrated to be a rate-limiting oncogene in transformation by RAS10, we examined the response of a cell line 
overexpressing CDC25A, as paradigm for the demonstration of compounds potency. The data confirmed that the 
compounds could effectively decrease viability of CDC25 overexpressing cells (Fig. 5).
Finally, we conducted studies in 3D-organoids, a system that reproduces architecture and function of the 
tissue of origin in reduced scale47 and in zebrafish as in vivo model of K-Ras-dependent tumors. Organoids 
obtained from stem cells of the intestinal crypts of Apc/K-Ras mice feature an internal cavity, corresponding to the 
crypt’s lumen, but lack the symmetry characteristic of this organ48. Fluorescence microscopy revealed decreased 
organoids size and acquisition of a differentiated state in response to CDC25 inhibitors, a pattern confirmed by 
qRT-PCR on selected markers (Fig. 6). These data are reminiscent of observations made on Cdc25B-/-/Cdc25C-/- 
knock-out mice where Cdc25A was conditionally disrupted (Cdc25Afl-) in all tissues of the adult organism8. In 
this triple knock-out background, the authors reported large loss of the small intestine and crypts atrophy due to 
Figure 7. CDC25 inhibitors cause tumor regression and absence of metastasis in a zebrafish K-Ras-dependent 
tumor model. (A) Fluorescent microscopy images of HCT116 tumor xenografts (shown in red) immediately 
after implantation (Day 0) in two-days old zebrafish larvae and three days (Day 3) after implantation and 
treatment with DMSO vehicle (Control), UPD-176 (176), UPD-140 (140) or UPD-738 (738), in five-days 
old zebrafish larvae. Primary tumors and metastatic sites are shown separately. Metastasized tumor cells are 
indicated with white arrows. Size-bars in primary tumor images and metastatic site images correspond to 
100 µm and 50 µm, respectively. (B,C) Quantifications of relative tumor volumes indicating the primary tumor 
size at day 3 relative to day 0 (B) or the number of metastasized tumor cells to the bone-marrow-like caudal 
hematopoietic plexus three days after tumor implantation (C). Results are shown as means (±SEM) of 17, 12, 
12 and 17 embryos in the control, UPD-176, UPD-140 and UPD-738 groups, respectively. P-values indicate 
comparison between control and drug treated groups.
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arrest at G1 and G2 phases of the cell cycle, which was paralleled by an increase of epithelial cell differentiation. 
As a whole, the triple knock-out studies and our data support the concept that blocking cell cycle progression 
through inhibition of CDC25 activity is beneficial to target tumor growth driven by mutant Ras and dependent 
on CDC25.
In zebrafish transparent embryos implanted with fluorescently labeled HCT116 cells, tumor growth/regres-
sion and metastasis can be accurately followed in vivo, over time, at single-cell resolution38. In this system, the 
efficacy of potential drug candidates can be accurately determined49,50. We obtained evidence that compounds 
bearing a pharmacophore common to NSC-663284, which was shown to have minimal antitumor activity in mice 
due to rapid metabolism20, are well tolerated and show clear anti-tumor efficacy in zebrafish xenograft models. 
Interestingly, compounds displaying the most potent effect in biochemical assays, showed the highest efficacy in 
the zebrafish model (Fig. 7), suggesting that these, and UPD-140 in particular, may be promising candidates for 
further investigation.
As a whole, the data reported in this study reveal the potential of novel naphthoquinone scaffolds acting as 
CDC25 inhibitors to target Ras-dependent tumors.
Materials and Methods
Chemistry. Commercially available chemicals were purchased from Sigma-Aldrich (Milan, Italy). For 
work-up and chromatographic purification, commercial grade solvents were used. Semi-preparative and prepara-
tive purifications of the synthesized compounds were carried out on Isolera One automated flash chromatography 
system (Biotage, Upsala, Sweden). The analytical profile of the synthesized molecules was in accordance with liter-
ature data (see below). 1H and 13C[1H] NMR spectra were recorded on a Bruker Avance III 400 MHz and a Bruker 
AMX 300 MHz spectrometers51. All spectra were recorded at room temperature. High-resolution mass spectra 
were recorded on an ESI-TOF Mariner from PerSeptive Biosystem (Stratford, Texas, USA), using electrospray 
ionization (ESI). Purity was assayed by HPLC, using a Varian Pro-Star system equipped with a Bio-Rad 
1706 UV–VIS detector and an Agilent C-18 column (5 mm, 4.6 mm 150 mm). Water (A) and acetonitrile (B) were used 
as mobile phases with an overall flow rate of 1 mL/min and the following analytical method: 0 min (90% A–10% B), 
15 min (10% A– 90% B), 20 min (10% A–90% B), 21 min (90% A–10% B), 255 min (90% A–10% B). Purity was 
over 97% (HPLC area).
General procedure for the synthesis of UPD-596 (2-(2,3,4-trihydroxyphenyl)-1,4-naphthoquinone), UPD-
597 (2-(2,4-dihydroxyphenyl)-1,4-naphthoquinone), UPD-786 (8-hydroxy-2-(2,3,4 trihydroxyphenyl) 
naphthalene-1,4-dione), UPD-787 (8-hydroxy-2-(2,4-dihydroxy-3-methylphenyl) naphthalene-1,4-dione), 
UPD-788 (8-hydroxy-2-(2,4,6-trihydroxyphenyl)naphthalene-1,4-dione), UPD-790 (8-hydroxy-2-(2,4-
dimethoxyphenyl)naphthalene-1,4-dione), UPD-140 (2-(2′,4′-dihydroxyphenyl)-8-hydroxy-1,4-naphthoquinone) 
and UPD-176 (5-hydroxy-2-(2,4-dihydroxyphenyl)naphthalene-1,4-dione). The preparation of the substi-
tuted naphthoquinones was performed according to previously reported procedures51,52. Briefly, the opportune 
naphthalene-1,4-dione (2 eq) and phenol (1 eq) were reacted in a mixture of acetic acid and 2 M H2SO4. After 2 h 
of stirring at room temperature under a nitrogen atmosphere, the reaction was stopped by the addition of water 
and neutralized with 5% sodium bicarbonate. The mixture was extracted with ethyl acetate, which was then evap-
orated to give the crude product. Purifications or separation of isomers were carried out by recrystallization or 
flash chromatography (n-hexane/ethyl acetate = 7:3 v/v).
General procedure for the synthesis of UPD-793 (3-(p-tolylthio)juglone) and UPD-795 (2-(3-methoxyphenylthio)-8-h
ydroxynaphthalene-1,4-dione). The preparation of the sulfur-containing naphthoquinone derivatives was per-
formed according to the previously reported procedure, with slight modifications51. Juglone (2 eq) and the oppor-
tune thiophenol (1 eq) were reacted in ethanol at room temperature. After 2 h of stirring at room temperature, 
the precipitate forming from the reaction mixture was filtered and recrystallized from ethanol to give the desired 
product.
General procedure for the synthesis of UPD-797 (8-hydroxy-2-(piperidin-1-yl)naphthalene-1,4-dione) and UPD-
798 (N-(5-hydroxy-1,4-naphthoquinon-3-yl)morpholine). The N-substituted naphthoquinones were prepared 
according to a previously reported procedure by reacting the precursor 3-Bromo juglone (1 eq) with a large 
excess of the appropriate amine (7 eq) in acetic acid. The work-up of the compounds was carried out following 
the reported procedure51.
Synthesis of UPD-724 (1,4-dihydroxy-6-anthraquinonecarboxylic acid). The compound was synthesized from 
trimellitic anhydride and hydroquinone by a Friedel Crafts reaction (AlCl3, NaCl, 150 °C, 7 h) followed by a mild 
air oxidation, according to a previously reported procedure53,54.
Synthesis of UPD-738 (5-hydroxynaphtho-1,4-quinone). 5-hydroxynaphtho-1,4-quinone (juglone) was prepared 
according to a literature procedure55,56.
Synthesis of UPD-1416 (4-Hydroxy-2-methylquinoline-5,8-dione) and UPD-1419 (2-methyl-5,8-dihydro-5,8- 
dioxoquinoline). UPD-1416 is a commercially available compound (Ark Pharm). UPD-1419 was prepared 
according to a previously reported procedure, allowing the preparation of 1,4-quinone derivatives starting from 
1,4-dimethoxybenzenes using NBS57.
Synthesis of UPD-1382 (5,8-diaminonaphthalene-1,4-dione). The compound was prepared according to the pro-
cedure reported in patent US239935558.
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In silico protein preparation. The crystal structure of human CDC25A and CDC25B were retrieved 
from Protein Data Bank (PDB codes: 2Z5X and 1QB0 respectively) and processed in order to remove ligands 
and water molecules. Hydrogen atoms were added to the protein structures using standard geometries with 
the Molecular Operating Environment (MOE) software26. To minimize contacts between hydrogen atoms, the 
structures were subjected to Amber99 force-field minimization until the root mean square (rms) of conjugate 
gradient was < 0.1 kcal⋅mol−1⋅Å−1 (1 Å = 0.1 nm), keeping the heavy atoms fixed at their crystallographic posi-
tions. Human CDC25A and CDC25C were built using a homology modeling approach implemented into MOE26 
with CDC25B as homologous template (PDB code: 1QB0). Sequence alignment was performed using the MOE 
Protein Align tool with BLOSUM62 as substitution matrix (CDC25A, 67% identity; CDC25C, 61% identity).
Generation of virtual library and hit selection. An in silico virtual library was built from a proprietary 
database of synthetic molecules (2075 compounds) upon 2D to 3D conversion of the molecules chemical struc-
ture, optimization of compound conformers and addition of Gasteiger partial charges (MOE Suite). The strategy 
for hit selection is described in the Results section.
In silico hit expansion/optimization. The structure of the first two hits, UPD-140 and UPD-176, pro-
vided a clue for the hit expansion/optimization phase through a Site Finder approach (MOE Suite), followed by 
a Molecular Docking protocol (Glide, Schrödinger Suite59). Site Finder allows the identification of pockets and 
surface sites by identifying regions of tight atomic packing using Alpha Shapes, a generalization of convex hulls 
developed in60 that has been successfully validated against several unrelated targets61,62. The procedure suggested 
two close cavities that are highly conserved in the three enzymes, one of them corresponding to the phosphatase 
catalytic site. Based on the Site Finder indications, a molecular docking process was performed using the Glide 
package XP procedure63 (Schrödinger Suite) and focusing on compounds featuring a quinone moiety.
Microscopy. Cells were grown in 35 mm CellView™ cell culture dishes with glass bottom (# 627870, 
Greiner-BioOne) at a density of 2.5 × 105 cells/ml in a humidified cell incubator maintained at 37 °C and 5% 
CO2. Cell were viewed by phase contrast microscopy with a 10x objective using an Olympus IX 81 motorized 
inverted microscope (Olympus, Hamburg, Germany) equipped with external temperature control chamber and 
CO2 bottle to maintain cells at 37 °C with 5% CO2. Transition through mitosis was documented by acquisition 
of four frames per hour over a period of 14 h using a CCD camera (Orca AG, Hamamatsu) and cellR® software 
(Olympus). HeLa-Kyoto cells (mCherry-H2B/EGFP-α-tubulin) were visualized by fluorescence microscopy with 
an Olympus IX 81 microscope using a 10x objective and selecting Ex. = 492 ± 18 nm/Em. = 535 ± 50 nm for the 
green channel and Ex. = 572 ± 23 nm/Em. = 645 ± 75 nm for the red channel.
Intestinal organoids culture. Intestinal crypts were isolated from Apc/K-Ras animals bearing Apc1638N and 
villin-driven K-RasG12V alleles with slight modifications36 of a previously described method64. Briefly, crypts were 
isolated and purified, embedded in 50 μl matrigel drops (Corning, 356231) and overlaid with 500 μl organoid 
medium Advanced DMEM/F12 (Life Technologies, 11320-082) containing 2 mM GlutaMAX (Life Technologies, 
35050-061), 10 mM HEPES buffer (Sigma, 83264-100ML-F), 0.5 U/ml Penicillin/Streptomycin (Life Technologies, 
15070-063), N2 (Life Technologies, 17502-048), B27 (Life Technologies, 12587-010)]. Organoids were expanded 
for 5 days in growth factor supplemented medium containing 50 ng/ml mEGF (Life Technologies, PMG8041), 
100 ng/ml mNoggin (Peprotech, 250–38) and 500 ng/ml hRSPO1 (R&D, 4645-RS-025). EGF and R-spondin were 
subsequently removed to select for organoids that had lost the wild-type Apc copy. The medium was changed 
every 2 days. Established mutant lines were passaged every four days by mechanical disruption with a bent P1000 
pipette tip.
In vivo tumor model. Implantation of HCT116 cells into zebrafish embryos were carried out essentially as 
previously described38. Briefly, HCT116 cells were cultured in McCoy’s medium supplemented with 10% FCS and 
penicillin/streptomycin until ~80% confluence, then labeled for 30 min at 37 °C in 6 μg/mL 1,1′-dioctadecyl-3,3,
3′,3′-tetramethylindocarbocyanine perchlorate (DiI, Sigma) in PBS followed by washing 3x in PBS. Labeled cells 
were implanted in the perivitelline space of 48 hours post-fertilization (hpf) wildtype (AB) zebrafish embryos, 
kept from the 1-cell stage in 1-phenyl-2-thiourea (PTU)-containing E3-water. Approximately 200–500 cells were 
implanted in each embryo, which were then transferred to E3 medium containing PTU as well as 10 μM UPD-
176, UPD-140 or UPD-738 appropriately diluted from stock solutions made in DMSO. As control, embryos were 
incubated in PTU-E3 with 0.1% DMSO (vehicle). Tumor-bearing embryos were incubated at 36 °C for three 
days and the change in tumor volume was evaluated as the size of the tumors at three days post-implantation 
(3 dpi) relative to the size immediately after implantation (0 dpi). Metastasis was evaluated at 3 dpi as the number 
of tumor cells present in the caudal hematopoietic plexus, the main metastatic site for tumors implanted in the 
perivitelline space.
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